Announcements Trials
Browse Landscape

Phase

Phase 3 5

Status

Completed 5

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 1

Conditions

Crohn Disease 3Lymphoma, Follicular 1Arthritis, Rheumatoid 1

Interventions

Cyclophosphamide 909Carboplatin 786pembrolizumab 743Paclitaxel 742Cisplatin 708Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 336Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Has results × Certolizumab Pegol × Clear all
NCT03357471 2019-10-25

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

UCB Pharma

Phase 3 Completed
70 enrolled 16 charts
Lymphoid

Lymphoma, Follicular

NCT00552058 2018-08-09

Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease

UCB Pharma

Phase 3 Completed
439 enrolled 25 charts

Crohn Disease

NCT00333788 2018-08-07

Welcome2

UCB Pharma

Phase 3 Completed
233 enrolled 31 charts

Crohn Disease

NCT01374971 2014-04-08

Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)

Arthritis Treatment Center, Maryland

Phase 3 Completed
12 enrolled 4 charts

Arthritis, Rheumatoid

NCT00297648 2011-08-31

MUSIC

UCB Pharma

Phase 3 Completed
89 enrolled 43 charts

Crohn Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡